

Supplementary Table S6. Phase II objective radiological response according to RECIST and mRECIST by central independent review		
Best Response	Treatment Group	
	Nintedanib, 200 mg bid (n = 62)	Sorafenib, 400 mg bid (n = 31)
RECIST, n (%)		
Disease control	51 (82.3)	28 (90.3)
Objective response	1 (1.6)	2 (6.5)
Complete response	0 (0.0)	0 (0.0)
Partial response	1 (1.6)	2 (6.5)
Stable disease	50 (80.6)	26 (83.9)
Progressive disease	8 (12.9)	1 (3.2)
Not evaluable	2 (3.2)	0 (0.0)
Unknown	1 (1.6)	2 (6.5)
mRECIST, n (%)		
Disease control	51 (82.3)	28 (90.3)
Objective response	7 (11.3)	6 (19.4)
Complete response	0 (0.0)	0 (0.0)
Partial response	7 (11.3)	6 (19.4)
Stable disease	44 (71.0)	22 (71.0)
Progressive disease	8 (12.9)	1 (3.2)
Not evaluable	2 (3.2)	0 (0.0)
Unknown	1 (1.6)	2 (6.5)

Abbreviations: RECIST, Response Evaluation Criteria in Solid Tumours; mRECIST, modified RECIST